Teleflex (NYSE:TFX) Upgraded to "Buy" at Wall Street Zen

Teleflex (NYSE:TFX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

A number of other equities research analysts have also commented on TFX. Mizuho set a $155.00 price objective on shares of Teleflex in a research note on Wednesday, April 16th. Truist Financial decreased their price target on Teleflex from $140.00 to $137.00 and set a "hold" rating for the company in a report on Monday, May 5th. Morgan Stanley dropped their price objective on Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a research note on Monday, May 5th. Bank of America cut Teleflex from a "neutral" rating to an "underperform" rating and decreased their target price for the stock from $235.00 to $140.00 in a research note on Tuesday, March 4th. Finally, Piper Sandler reissued a "neutral" rating and issued a $140.00 price target (down from $255.00) on shares of Teleflex in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Teleflex currently has an average rating of "Hold" and a consensus target price of $164.63.

Teleflex Trading Up 1.8%

Shares of TFX stock traded up $2.10 during trading hours on Friday, hitting $120.16. 458,141 shares of the company's stock traded hands, compared to its average volume of 628,509. The stock has a market cap of $5.31 billion, a PE ratio of 37.91, a price-to-earnings-growth ratio of 1.85 and a beta of 1.10. The stock's 50 day simple moving average is $125.16 and its 200 day simple moving average is $149.16. The company has a quick ratio of 1.32, a current ratio of 2.28 and a debt-to-equity ratio of 0.44. Teleflex has a 12 month low of $115.94 and a 12 month high of $249.91.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, beating analysts' consensus estimates of $2.88 by $0.03. Teleflex had a return on equity of 14.73% and a net margin of 4.96%. The firm had revenue of $700.67 million for the quarter, compared to analyst estimates of $699.37 million. During the same quarter in the previous year, the company posted $3.21 EPS. The business's revenue was down 5.0% on a year-over-year basis. On average, sell-side analysts anticipate that Teleflex will post 13.98 EPS for the current year.

Hedge Funds Weigh In On Teleflex

A number of hedge funds have recently added to or reduced their stakes in the stock. Empowered Funds LLC bought a new stake in Teleflex during the fourth quarter worth $259,000. Vontobel Holding Ltd. grew its stake in shares of Teleflex by 21.9% in the 4th quarter. Vontobel Holding Ltd. now owns 1,393 shares of the medical technology company's stock worth $248,000 after acquiring an additional 250 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in shares of Teleflex by 28.2% in the fourth quarter. Sanctuary Advisors LLC now owns 6,251 shares of the medical technology company's stock valued at $1,143,000 after purchasing an additional 1,374 shares during the last quarter. Alberta Investment Management Corp bought a new position in shares of Teleflex during the fourth quarter valued at about $2,011,000. Finally, Bryn Mawr Capital Management LLC purchased a new position in Teleflex during the fourth quarter worth about $694,000. Institutional investors and hedge funds own 95.62% of the company's stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.